论文部分内容阅读
目的探讨重组人Elafin对大鼠肝脏缺血再灌注损伤的保护作用。方法建立大鼠肝缺血再灌注损伤模型,给予不同浓度的重组人Elafin对其进行治疗,检测血清中谷丙转氨酶(ALT)、谷草转氨酶(AST)及乳酸脱氢酶(LDH)含量,并对肝脏病理组织学改变进行观察。结果缺血再灌注后大鼠肝组织损害较重,血清ALT、AST及LDH水平明显升高(P<0.001),若手术前给予大鼠一定浓度的重组人Elafin可对肝脏缺血再灌注损伤起到一定的保护作用。结论重组人Elafin对肝脏缺血再灌注损伤有一定的保护作用。
Objective To investigate the protective effect of recombinant human Elafin on hepatic ischemia-reperfusion injury in rats. Methods The rat model of hepatic ischemia-reperfusion injury was established. The rats were treated with different concentrations of recombinant human Elafin, and the levels of ALT, AST and LDH in the serum were detected. Histopathological changes of liver were observed. Results After ischemia-reperfusion, the liver tissue of rats was severely damaged and the levels of serum ALT, AST and LDH were significantly increased (P <0.001). If a certain concentration of recombinant human Elafin was administered before surgery, the hepatic ischemia-reperfusion injury Play a protective role. Conclusion Recombinant human Elafin has a protective effect on liver ischemia-reperfusion injury.